New drug duo takes on tough tumors
NCT ID NCT05327946
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants will receive infusions every 3 weeks for up to 2 years if they benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida, 34232, United States
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.